CNS Pharmaceuticals (FRA:BE50) Change In Inventory: €0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BE50 CNS Pharmaceuticals Inc FRA:BE50
35 GF Score
Price €0.61
! 1 Warning Sign
View Full Analysis

What is CNS Pharmaceuticals Change In Inventory?

CNS Pharmaceuticals FRA:BE50 35 Change In Inventory is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:BE50 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

CNS Pharmaceuticals's change in inventory for the quarter that ended in Jun. 2026 was €0.00 Mil. It means CNS Pharmaceuticals's inventory stayed the same from Mar. 2026 to Jun. 2026 .

CNS Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2025 was €0.00 Mil. It means CNS Pharmaceuticals's inventory stayed the same from Dec. 2024 to Dec. 2025 .

CNS Pharmaceuticals's Total Inventories for the quarter that ended in Jun. 2026 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

CNS Pharmaceuticals  (FRA:BE50) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

CNS Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=0/0*365 / 4
=N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

CNS Pharmaceuticals's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=0 / 0
=N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

CNS Pharmaceuticals's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNS Pharmaceuticals Change In Inventory Related Terms

CNS Pharmaceuticals Change In Inventory Historical Data

* Premium members only.

The historical data trend for CNS Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNS Pharmaceuticals Change In Inventory Chart

CNS Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Inventory
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

CNS Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:BE50
35GF Score
CNS Pharmaceuticals Inc FRA:BE50
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CNS Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of €0.00 Mil mean?
CNS Pharmaceuticals (FRA:BE50) has a Change In Inventory of €0.00 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for CNS Pharmaceuticals and its competitors.
Is CNS Pharmaceuticals' Change In Inventory too high?
CNS Pharmaceuticals' current Change In Inventory is €0.00 Mil. Overall, CNS Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does CNS Pharmaceuticals' Change In Inventory compare to MTVA and TRAW?
CNS Pharmaceuticals' Change In Inventory of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for CNS Pharmaceuticals and its competitors. CNS Pharmaceuticals's current Change In Inventory is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNS Pharmaceuticals stock overvalued right now?
CNS Pharmaceuticals (FRA:BE50) has a current Change In Inventory of €0.00 Mil. The current Change In Inventory is €0.00 Mil. CNS Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For CNS Pharmaceuticals (FRA:BE50), the current Change In Inventory is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CNS Pharmaceuticals Business Description

Other Exchanges CNSP:USA
Address 2100 West Loop South, Suite 900, Houston, TX, USA, 77027
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
35GF Score

Get the complete analysis for FRA:BE50

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.61
Price